Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06933329 · ClinicalTrials.gov registry record · Phase 2
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by BicycleTx Limited.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
- 20
- Study locations
NCT06933329 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by BicycleTx Limited. The registered enrollment target is 73 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT06933329, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by BicycleTx Limited.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with previously treated NECTIN4-amplified advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior line of systemic therapy in the advanced/metastatic setting (see inclusion criteria below). The study will comprise of 2 cohorts: Cohort A (non-squamous NSCLC) and Cohort B (squamous NSCLC).
Conditions Studied
Interventions
- DRUG Zelenectide pevedotin
Study Locations (20)
Other
- Institut Bergonie - Bordeaux
- Centre Hospitalier Intercommunal de Créteil - Créteil
- Centre Leon Berard - Lyon
- Institut Curie - Paris
- Les Hôpitaux Universitaires de Strasbourg - Strasbourg
- Hopital Foch - Suresnes
- Complejo Hospitalario Universitario A Coruña - A Coruña
- Hospital Clinic de Barcelona - Barcelona
- Hospital Universitario 12 de Octubre - Madrid
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Texas
- Texas Oncology - Central South - Austin
- Texas Oncology - DFW - Dallas
Alaska
- Alaska Oncology and Hematology, LLC - Anchorage
California
- University of California, Davis Comprehensive Cancer Center - Sacramento
Montana
- St. Vincent Regional Hospital - Cancer Centers of Montana - Billings
New York
- Clinical Research Alliance, Inc - Westbury
Ohio
- Oncology Hematology Care Clinical Trials, LLC - Fairfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2025-07-18 |
| Est. Completion | 2029-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06933329
The ClinicalTrials.gov registry entry for NCT06933329 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The listed sponsor is BicycleTx Limited, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Zelenectide pevedotin is the first listed.
NCT06933329 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT06933329 about?
NCT06933329 is a clinical study titled "Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer". This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with previously treated NECTIN4-amplified advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior line of systemic therapy in th...
What is the current status of trial NCT06933329?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2025-07-18. Estimated completion is 2029-02-28.
What conditions does trial NCT06933329 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06933329?
The interventions under investigation include: Zelenectide pevedotin (DRUG).
Who is sponsoring clinical trial NCT06933329?
This trial is sponsored by BicycleTx Limited, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06933329 being conducted?
This trial has 20 study locations across Alaska, California, Massachusetts, Montana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.